BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Capecitabine: trial readouts and FDA decisions
9 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 12 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Qilu Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., BeyondBio Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AskGene Pharma, Inc., Jiangsu HengRui Medicine Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., CStone Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | recruiting | 27 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies | recruiting | 154 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophag | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | not yet recruiting | 100 |
| 2026-12-30 est. | P3 | AskGene Pharma, Inc. | NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma | active not recruiting | 780 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuz | active not recruiting | 381 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-11 est. | P3 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | NCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or | Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metasta | recruiting | 486 |
| 2027-01-15 est. | P2 | Biostar Pharma, Inc. | NCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | 120 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Nasopharyngeal Carcinoma | active not recruiting | 386 |
| 2026-10 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer | CLDN18.2-positive Advanced Biliary Tract Cancer | not yet recruiting | 120 |
| 2026-09-30 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With | Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metasta | not yet recruiting | 28 |
| 2026-09 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic | Recurrent Metastatic Nasopharyngeal Carcinoma | not yet recruiting | 500 |
| 2026-08-28 | P3 | Arcus Biosciences, Inc. RCUS | NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That C | Advanced Upper Gastrointestinal Tract Adenocarcinoma | completed | 1040 |
| 2026-08-18 est. | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | active not recruiting | 350 |
| 2026-08-12 | P3 | DualityBio Inc. | NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Metastatic Breast Cancer | active not recruiting | 541 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Canc | HR+HER2- Breast Cancer | active not recruiting | 383 |
| 2026-07-29 | P2 | Processa Pharmaceuticals PCSA | NCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer | terminated | 20 |
| 2026-07-15 | P3 | Jazz Pharmaceuticals JAZZ | NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | active not recruiting | 920 |
| 2026-06-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | Advanced Solid Tumor | not yet recruiting | 360 |
| 2026-06 est. | P1/P2 | CG Pharmaceuticals, Inc | NCT05249101 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | active not recruiting | 70 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.